亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

乙酰基四肽-5/眼絲氨肽 眼部多肽 美容多肽

 
 
單價 1.00 / g對比
銷量 暫無
發貨 四川成都市付款后3天內
庫存 1000g起訂1g
品牌 成都云希
CAS號 820959-17-9
分子量 429.29g/mol
分子式 C20H28N8O7
過期 長期有效
更新 2021-07-02 10:35
 

成都云希化工有限公司

企業會員第6年
資料未認證
保證金未繳納
詳細說明

云希產品簡介----乙酰基四肽-5/眼絲氨肽

乙酰基四肽-5主要用于祛除眼袋和黑眼圈,效果明顯。

 

云希產品參數----乙酰基四肽-5/眼絲氨肽

 

中文名稱:乙酰基四肽-5/眼絲氨肽/麗眼肽

英文名稱:Acetyl Tetrapeptide-5/Eyeseryl

CAS號:820959-17-9

純度:≥98%

分子量 :429.29g/mol

分子式 :C20H28N8O7

外觀:白色粉末或液體

儲存條件:2 ℃~8 ℃

包裝規格(粉末):1g, 10g, 100g

包裝規格(液體):20ml/瓶,1KG/瓶

應用:化妝品原料

 

云希功效與應用----乙酰基四肽-5/眼絲氨肽

特別適合于眼部產品,消除眼袋和黑眼圈

提高皮膚彈性和光滑度。

 

云希作用機理----乙酰基四肽-5/眼絲氨肽

隨著年齡增大,皮膚逐漸喪失彈性,肌肉功能弱化,而使眼睛周圍皮膚松弛形成眼袋。眼瞼部位水分的過度積累即眼瞼水腫。乙酰四肽-5能夠消除水腫,提高皮膚彈性和光滑度。膠原蛋白相互交聯,也是產生眼袋的原因,乙酰基四肽-5能夠抑制糖化作用,而達到減輕眼袋和抗皺的功效。

 

舉報收藏 0評論 0
更多>本企業其它產品
云希專注勝肽乙酰基六肽-49/DELISENS 乙酰基六肽-1 乙酰基四肽-2 三肽-10瓜氨酸/核心蛋白聚糖肽 Polypeptide-23 乙酰基六肽-7抗衰多肽 Sh-Decapeptide-7 Oligopeptide-21/寡肽21
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |